$2.87
1.77% yesterday
Nasdaq, Dec 24, 10:16 pm CET
ISIN
US4622601007
Symbol
IOVA

Iovance Biotherapeutics Inc Stock price

$2.87
+0.37 14.80% 1M
+0.99 52.66% 6M
-4.53 61.22% YTD
-4.62 61.68% 1Y
-3.25 53.10% 3Y
-46.68 94.21% 5Y
-4.89 63.02% 10Y
-2.34 44.90% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.05 1.77%
ISIN
US4622601007
Symbol
IOVA
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$819.7m
Net debt
positive
Cash
$300.8m
Shares outstanding
385.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.5 | 4.2
EV/Sales
3.3 | 3.1
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
78.0%
Return on Equity
-52.4%
ROCE
-51.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$250.4m | $264.1m
EBITDA
$-394.9m | $-368.1m
EBIT
$-403.9m | $-402.8m
Net Income
$-397.6m | $-411.8m
Free Cash Flow
$-351.8m
Growth (TTM | estimate)
Revenue
175.6% | 60.9%
EBITDA
-1.0% | -3.8%
EBIT
6.1% | -3.9%
Net Income
3.0% | -10.7%
Free Cash Flow
6.0%
Margin (TTM | estimate)
Gross
24.0%
EBITDA
-157.7% | -139.4%
EBIT
-161.3%
Net
-158.8% | -156.0%
Free Cash Flow
-140.5%
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
32.3%
Employees
838
Rev per Employee
$200.0k
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

12x Buy
67%
5x Hold
28%
1x Sell
6%

Analyst Opinions

18 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
67%
Hold
28%
Sell
6%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
250 250
176% 176%
100%
- Direct Costs 190 190
130% 130%
76%
60 60
646% 646%
24%
- Selling and Administrative Expenses 156 156
11% 11%
62%
- Research and Development Expense 299 299
0% 0%
119%
-395 -395
1% 1%
-158%
- Depreciation and Amortization 9.01 9.01
77% 77%
4%
EBIT (Operating Income) EBIT -404 -404
6% 6%
-161%
Net Profit -398 -398
3% 3%
-159%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SAN CARLOS, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 18, 2025 (the “Date of Grant”), the Company approved the grant of indu...
Positive
The Motley Fool
18 days ago
CRISPR Therapeutics' approved medicine is making slow progress, but it has an exciting pipeline. Iovance Biotherapeutics is generating decent revenue, but it faces significant obstacles.
Neutral
GlobeNewsWire
about one month ago
SAN CARLOS, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on November 20, 2025 (the “Date of Grant”), the Company approved the grant of indu...
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today